This article was first published on September 10, 2018. It was last reviewed, updated, or edited on May 8, 2024. By John O’Reardon, MD (bio) In September 2018, the FDA cleared a transcranial magnetic stimulation (TMS) device to be marketed for the adjunctive treatment of obsessive-compulsive disorder (OCD). This was a boost for sufferers of…